Atossa appoints Heather Rees as CFO, increases authorized shares to 360M

ATOSSA THERAPEUTICS, INC.

Heather Rees appointed CFO effective June 27, 2024; salary set at $439,700 with 40% bonus target.
Rees granted 577,700 stock options vesting quarterly over two years under the 2020 Plan.
Stockholders approved increase in authorized common shares from 175M to 350M (total authorized to 360M).
Amendment and restatement of 2020 Stock Incentive Plan approved, adding 12M shares.

item 5.02 item 5.03 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Heather Rees

Chief Financial Officer

ATOS · ATOSSA THERAPEUTICS, INC.

Effective: 2024-06-27
Filed: July 2, 2024, 7:59 PM ET

On June 27, 2024, the Board of Directors (the “Board”) of the Company appointed Heather Rees, previously the Company’s Senior Vice President, Finance and Accounting, to serve as Chief Financial Officer and to continue serving as principal financial and accounting officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Heather Rees was appointed as Chief Financial Officer at ATOSSA THERAPEUTICS, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 27, 2024, the Board of Directors (the “Board”) of the Company appointed Heather Rees, previously the Company’s Senior Vice President, Finance and Accounting, to serve as Chief Financial Officer and to continue serving as principal financial and accounting officer, effective immediately.

View on SEC.gov

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-080497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.